Clinical experience and treatment considerations with vesicular monoamine transport 2 inhibitors
Vesicular monoamine transporter 2 inhibitors (VMAT2i) are currently Food and Drug Administration–approved for the treatment of Huntington disease chorea and tardive dyskinesia. Additionally, they are often used for other hyperkinetic movement disorders in clinical practice. Due to a lack of head-to-...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association of Psychiatric Pharmacists
2024-12-01
|
| Series: | Mental Health Clinician |
| Subjects: | |
| Online Access: | https://theijpt.org/doi/pdf/10.9740/mhc.2024.12.304 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|